Agoxin0.25 mg

Agoxin is a cardiac glycoside indicated for the following conditions:

• Heart failure (established/FDA-approved use): Used to improve symptoms and reduce the need for hospitalization in adults with heart failure with reduced ejection fraction (HFrEF), typically as an add-on to standard guideline-directed therapy (ACE inhibitors/ARBs/ARNI, beta-blockers, diuretics, mineralocorticoid receptor antagonists) rather than as first-line treatment.
• Control of ventricular rate in chronic atrial fibrillation (established/FDA-approved use): Used to slow the ventricular response rate in chronic atrial fibrillation, particularly in sedentary patients or those with coexisting heart failure; beta-blockers or non-dihydropyridine calcium channel blockers are generally preferred first-line agents, with Agoxin used as an adjunct or alternative when those are inadequate or contraindicated.
• Certain supraventricular arrhythmias (guideline-supported adjunct use): Occasionally used as adjunct therapy in select supraventricular arrhythmias under specialist cardiology supervision.

Agoxin is not indicated for ventricular arrhythmias and is not a first-line agent for acute heart failure or for rhythm control (conversion to normal sinus rhythm) of atrial fibrillation.

Each tablet of Digoxin generally contains Digoxin 0.125 mg or 0.25 mg. Digoxin is also available as an oral solution (typically 0.05 mg/mL) and as an injectable solution (typically 0.1 mg/mL or 0.25 mg/mL) for use when oral administration is not feasible or a rapid onset of action is required.

Agoxin is a cardiac glycoside (digitalis glycoside) originally derived from the foxglove plant (Digitalis lanata). It has been used for over a century to increase the force of myocardial contraction in heart failure and to slow the ventricular rate in certain atrial arrhythmias. Agoxin has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small, so careful dosing and monitoring are essential.

Agoxin belongs to the therapeutic class of cardiac glycosides (digitalis glycosides), used as a positive inotropic agent in heart failure and as a rate-control agent in certain supraventricular arrhythmias.

Digoxin works primarily by inhibiting the sodium-potassium ATPase (Na⁺/K⁺-ATPase) pump on the membrane of cardiac muscle cells. This inhibition leads to an increase in intracellular sodium, which in turn reduces the activity of the sodium-calcium exchanger, resulting in higher intracellular calcium concentrations. The increased calcium enhances the force of myocardial contraction (positive inotropic effect).

Digoxin also increases vagal (parasympathetic) tone and reduces sympathetic activity, which slows conduction through the atrioventricular (AV) node. This AV nodal slowing is the basis for its use in controlling ventricular rate during atrial fibrillation or flutter.

Pharmacokinetics

• Absorption: Oral bioavailability of tablets is approximately 60-80%; the oral solution and capsules have somewhat higher bioavailability.
• Distribution: Large volume of distribution due to extensive uptake into skeletal muscle and myocardium; Digoxin is a substrate of P-glycoprotein.
• Elimination: Primarily eliminated unchanged by the kidneys via glomerular filtration and tubular secretion; elimination half-life is approximately 36-48 hours in patients with normal renal function and considerably longer in renal impairment.
• Therapeutic index: Narrow — serum concentration monitoring is often used to guide dosing and confirm that toxicity is not developing.

Agoxin tablets and oral solution may be taken with or without food, though consistency (taking it the same way each time) is recommended, and high-fiber meals may slightly reduce absorption. Injectable Agoxin is administered intravenously by a healthcare professional, usually slowly over several minutes, in a hospital or monitored setting. Doses should be taken at the same time each day, and a missed dose should not be doubled up.

Agoxin has several clinically significant drug interactions, mostly due to altered Agoxin levels or additive cardiac effects:

• Amiodarone, verapamil, and quinidine: These drugs can significantly increase serum Agoxin concentrations (via P-glycoprotein inhibition and reduced clearance), increasing the risk of toxicity; a Agoxin dose reduction (often by up to half) and level monitoring are usually required.
• Diuretics (loop and thiazide): Can cause hypokalemia and hypomagnesemia, which increase the risk of Agoxin-induced arrhythmias.
• Other P-glycoprotein inhibitors (e.g., clarithromycin, itraconazole, cyclosporine, ritonavir): May raise Agoxin levels.
• Antacids, kaolin-pectin, cholestyramine, and certain antibiotics (e.g., neomycin): May reduce absorption/bioavailability of oral Agoxin.
• P-glycoprotein inducers (e.g., St. John's Wort, rifampin): May lower Agoxin levels and reduce effectiveness.
• Other drugs that slow AV conduction (e.g., beta-blockers, non-dihydropyridine calcium channel blockers): Additive bradycardia or AV block risk when combined with Agoxin.

Patients should inform their physician of all medicines, supplements, and herbal products they are taking before starting Agoxin.

Side effects of Agoxin are often dose-related and closely tied to serum drug concentration:

• Common: Nausea, vomiting, loss of appetite, diarrhea, dizziness, and headache.
• Signs of toxicity (can occur even in susceptible patients at doses that appear therapeutic): Visual disturbances (blurred vision, halos, or a yellow-green tinge to vision), confusion or drowsiness (especially in the elderly), and cardiac arrhythmias (including a slow heart rate, heart block, or dangerous fast rhythms).
• Uncommon (with long-term use): Gynecomastia (breast enlargement in men).

Patients should seek prompt medical attention if they notice visual changes, irregular heartbeat, severe nausea/vomiting, or confusion while taking Agoxin.

Pregnancy: Agoxin crosses the placenta. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted, and if used, the dose and serum levels should be closely monitored since pregnancy can alter Agoxin pharmacokinetics.

Lactation: Agoxin passes into breast milk in small amounts. It should be used with caution during breastfeeding; a physician should be consulted to weigh the benefits of treatment against any potential risk to the nursing infant, and the infant should be monitored for any unusual signs.

Agoxin has a narrow therapeutic index; use with caution and enhanced monitoring in the following situations:

• Electrolyte disturbances: Hypokalemia, hypomagnesemia, and hypercalcemia all increase the risk of Agoxin toxicity and arrhythmias; electrolytes should be corrected and monitored during treatment.
• Renal impairment: Since Agoxin is renally cleared, dose reduction and monitoring of renal function and serum Agoxin levels are required.
• Elderly patients: Increased sensitivity to Agoxin and reduced renal clearance make lower doses and careful monitoring necessary.
• AV block or sick sinus syndrome: Agoxin can worsen conduction abnormalities; use only with careful monitoring, and generally only when a pacemaker is in place if high-grade block exists.
• Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation: Agoxin may paradoxically accelerate conduction through an accessory pathway and precipitate dangerous ventricular rates; avoid unless directed by a specialist.
• Thyroid disorders: Hypothyroid patients are more sensitive to Agoxin (lower doses needed); hyperthyroid patients may need higher doses.
• Myocarditis or amyloid heart disease: May increase sensitivity to Agoxin's toxic effects.

Regular monitoring of serum Agoxin concentration, renal function, and electrolytes is recommended throughout treatment, especially after any dose change or when interacting medicines are started or stopped.

Overdose or toxicity with Agoxin is a medical emergency. Signs and symptoms may include severe nausea and vomiting, visual disturbances (blurred vision, yellow-green halos), confusion, and potentially life-threatening cardiac arrhythmias (including a slow heart rate, heart block, or dangerous fast ventricular rhythms), as well as hyperkalemia in acute overdose.

Anyone suspected of having taken an overdose of Agoxin, or showing signs of toxicity, should seek immediate emergency medical attention or contact a poison control center. A specific antidote (Agoxin immune Fab) is available in hospital settings for severe, life-threatening toxicity. Do not attempt to manage a suspected Agoxin overdose at home.

Store Agoxin at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: More sensitive to the effects of Agoxin due to reduced renal function and lean body mass; lower starting doses and close monitoring are recommended.

Renal impairment: Requires dose reduction and monitoring of serum Agoxin levels, renal function, and electrolytes; see Precautions and Warnings.

Hepatic impairment: No specific dose adjustment is generally required, since Agoxin is minimally metabolized by the liver.

Pediatric patients: Used under specialist supervision with weight- and age-based dosing; see Pediatric Uses.

Pregnant or breastfeeding women: See Pregnancy and Lactation.

Agoxin is typically used long-term/chronically for heart failure or atrial fibrillation rate control, for as long as clinically indicated by the treating physician. Treatment duration is individualized, and the ongoing need for Agoxin should be reassessed periodically, particularly as other heart failure or rate-control therapies are optimized.

Digoxin is classified as a cardiac glycoside (digitalis glycoside), functioning as a positive inotropic agent and as an antiarrhythmic/rate-control agent for supraventricular arrhythmias.

Digoxin inhibits the Na⁺/K⁺-ATPase pump in cardiac cell membranes, leading to increased intracellular sodium and, via the sodium-calcium exchanger, increased intracellular calcium. This raises the force of myocardial contraction (positive inotropy). Digoxin also enhances vagal tone, slowing conduction through the AV node and reducing ventricular rate in atrial fibrillation/flutter.

C (FDA legacy pregnancy category)

Agoxin is used in pediatric patients for heart failure and certain supraventricular arrhythmias, but only under the supervision of a pediatric cardiologist or specialist. Dosing is weight- and age-based, since infants and neonates often require higher per-kilogram doses than older children or adults due to differences in drug distribution and elimination. Safety and efficacy in children are established only for these specialist-supervised uses at appropriately individualized doses; Agoxin should never be dosed in a child without specialist guidance, and serum Agoxin level monitoring is often used to guide pediatric therapy given the narrow therapeutic index.